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The biosynthesis of endogenous brain-derived neurotrophic
factor (BDNF) has thus far been examined in neurons where it is
expressed at very low levels, in an activity-dependent fashion. In
humans, BDNF has long been known to accumulate in circulat-
ing platelets, at levels far higher than in the brain. During the
process of blood coagulation, BDNF is released from platelets,
which has led to its extensive use as a readily accessible bio-
marker, under the assumption that serum levels may somehow
reflect brain levels. To identify the cellular origin of BDNF in
platelets, we established primary cultures of megakaryocytes,
the progenitors of platelets, and we found that human and rat
megakaryocytes express the BDNF gene. Surprisingly, the pat-
tern of mRNA transcripts is similar to neurons. In the presence
of thapsigargin and external calcium, the levels of the mRNA
species leading to efficient BDNF translation rapidly increase.
Under these conditions, pro-BDNF, the obligatory precursor of
biologically active BDNF, becomes readily detectable. Mega-
karyocytes store BDNF in -granules, with more than 80% of
them also containing platelet factor 4. By contrast, BDNF is
undetectable inmousemegakaryocytes, in line with the absence
of BDNF in mouse serum. These findings suggest that altera-
tions of BDNF levels in human serum as reported in studies
dealing with depression or physical exercise may primarily
reflect changes occurring in megakaryocytes and platelets,
including the ability of the latter to retain and release BDNF.
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BDNF2 is a secretory protein regulating the development and
function of neural circuits (1, 2). The functional relevance of
BDNF in humans is firmly established following the discovery
of polymorphisms and loss-of-allele mutations associated with
deficits ranging from subtle memory alterations (3) to severe
symptoms early in life (4). The cDNA sequence of BDNF pre-
dicts that like other cystine-knot proteins, BDNF is first synthe-
sized as a precursor protein, referred to as pro-BDNF ensuring
the proper formation of disulfide bridges and of a biologically
active, mature neurotrophin (5, 6). Numerous experiments
with various artificial expression systems have confirmed this
view, in line with the results of early experiments with nerve
growth factor (7). So far, only a very small number of studies
have been performed addressing the question of the biosynthe-
sis, storage, and secretion of endogenous BDNF (8, 9). As a
result of the scarcity of the protein in neurons, most studies
used instead overexpression paradigms, leading to uncertain-
ties as to whether the processing of pro-BDNF takes place
within neurons or also in the extracellular space following the
secretion of pro-BDNF. Human platelets contain between
100–1,000-fold more BDNF than brain tissue when brain and
platelets are compared on a protein basis (10–12). As it appears
unlikely that the biosynthesis of BDNF takes place in platelets,
we established primary cultures of megakaryocytes (Mks), the
progenitors of platelets. Beyond questions related to the bio-
synthesis of endogenous BDNF and to the productive expres-
sion of its gene in non-neuronal cells, the question of the origin
of BDNF in humanblood and serum is ofwider interest. Indeed,
BDNF levels in human serum are widely used as a biomarker
speculated to somehow reflect brain levels. Thus, countless
studies have reported decreased BDNF levels in serum inmood
disorders, including depression (13), although by contrast
physical exercise has been found to increase them (14).
Experimental Procedures
Reagents—For recombinant proteins, BDNF produced in
Escherichia coli was from Amgen/Regeneron partners (Tarry-
town,NY). Cleavage-resistantmouse pro-BDNF and the BDNF
pro-peptide were produced in COS-7 cells transfected with the
corresponding cDNA (15). Stem cell factor and thrombopoi-
etin (TPO) were from R&D Systems (Abingdon, UK). Interleu-
kin-1 (IL1-) was from Miltenyi Biotec (Bisley, Surrey, UK).
Human recombinant fibrinogen was from EMD-Millipore
(Calbiochem; Darmstadt, Germany). The mouse monoclonal
anti-BDNF 3C11 was from Icosagen (Tartu, Estonia). BDNF
antibodies directed againstmature BDNF recognize themouse,
rat, and human protein with equal affinity as the corresponding
amino acid sequence is identical. The mouse monoclonal anti-
pro-BDNF H100G was from GeneCopoeia Inc. (Rockville,
MD). The monoclonal anti-BDNF#9 was used as described
(15). The chicken anti--actin Ab13822, the rabbit anti-PF4
Ab129183, and the goat anti-chicken HRP-conjugated second-
ary antibodyAb97135were fromAbcam (Cambridge,UK). The
donkey anti-mouse HRP-conjugated secondary antibody was
from Promega (Madison, WI). Alexa Fluor-488 donkey anti-
mouse IgG secondary antibody, Alexa Fluor-594 donkey anti-
rabbit IgG secondary antibody, and phalloidin-TRITC were
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purchased from Invitrogen. Hanks’ balanced salt solution,
Iscove’s modified Dulbecco’s medium, HEPES, fetal bovine
serum (FBS), L-glutamine, and penicillin/streptomycin were
from Invitrogen. Cellgro SCGM medium was from Cellgenic
(Freiburg, Germany). All other reagents, including thapsigargin
and ionomycin, were of analytical grade and were purchased
from Sigma (Dorset, UK).
Cell Culture and Isolation—Approximately 10-week-old
CD1 or C57BL/6 mice andWistar rats were sacrificed by rising
CO2 inhalation and blood subsequently drawn by cardiac punc-
ture using acid citric dextrose-B tubes (BD Vacutainer, BD;
Plymouth, UK). Femurs and tibias of CD1 orC57BL/6mice and
Wistar rats were removed, and bone marrow was extracted by
flushing the bones with Hanks’ balanced salt solution contain-
ing 0.38% sodium citrate, 1 mM adenosine, 2 mM theophylline,
and 5% heat-inactivated FBS. After lysis of the red cells, the
suspensionwas passed through a 40-mstrainer, and the pellet
was resuspended in culturemedium (Iscove’smodifiedDulbec-
co’s medium with L-glutamine, 25 mM HEPES, 5% heat-inacti-
vated FBS, 100 units/ml penicillin, and 100 g/ml streptomy-
cin) containing 25 ng/ml stem cell factor and TPO. After 6–7
days of culture in vitro, mature Mks were purified on a 1.5–3%
bovine serum albumin gradient and cultured in Cellgro SCGM
medium for up to 16 h. Hippocampi and lungs were dissected
and kept frozen at80 °C until use. Human samples, both neo-
natal cord blood and adult peripheral blood, were obtained
after securing informed consent following a protocol approved
by the National Research Ethics Service. CD34-positive cells
(98%) were isolated by magnetic cell sorting, cultured for 10
days in Cellgro SCGMmedium containing TPO and IL1-, and
analyzed by flow cytometrywith 70–90%CD41a and 20–60%
CD42a cells representing committed progenitors and mature
Mks, respectively. Platelet-rich plasma was obtained from
either animal or human samples by centrifugation of acid citric
dextrose-B tubes at 200 g for 20 min in the presence of pros-
taglandin-E1 (1 M) and apyrase (1 unit/ml) to prevent cellular
activation. Platelets were pelleted from platelet-rich plasma by
centrifugation at 1,100 g for 10 min and lysed immediately.
Western Blot andDensitometric Analyses—Platelets andMks
were lysed for 30 min on ice in a buffer containing 50 mM Tris-
HCl, pH 7.4, 150 mMNaCl, 1 mM EDTA, 1% Triton X-100, and
0.2% sodium deoxycholate, supplemented with protease and
phosphatase inhibitormixturemix, 10M1,10-phenanthroline
monohydrate, 10 mM 6-aminohexanoic acid and 10 g/ml
aprotinin. After sonication (1 pulse, 50% amplitude), insoluble
debris was removed by centrifugation. Proteins were separated
on 4–12% NuPAGE gradient gels containing SDS (Invitrogen)
and transferred to nitrocellulose membranes using the semi-
dry Trans-Blot unit (Bio-Rad, Hertfordshire, UK). To allow the
detection of the BDNF pro-peptide (15), the membranes were
fixed after transfer with 2.5% glutaraldehyde for 30min at room
temperature and subsequently incubated for 2 h with blocking
solution (3% blocking reagent (Invitrogen) and 3% BSA in
TBS-T) and then probed overnight at 4 °C with anti-BDNF
3C11 (1:2,000), anti-pro-BDNF H1001G (1:1,000), or chicken
anti--actin (1:2,000). Binding of primary antibodies was visu-
alized with donkey anti-mouse HRP-conjugated secondary
antibodies (1:10,000) or goat anti-chickenHRP-conjugated sec-
ondary antibody (1:5,000). Chemiluminescence was developed
using the Lumi Glo Reverse Western blotting substrate (Cell
Signaling Technology, Danvers, MA). Care was taken in all
experiments to ensure that the signal was well within the linear
range, and densitometry was carried out using ImageJ software.
BDNF ELISA Determinations—BDNF sandwich ELISA was
performed using a combination of monoclonal antibodies as
described previously (16), with the following modifications.
Streptavidin high binding capacity coated white plates (Pierce)
were incubated overnight at room temperature with 10 g/ml
mouse anti-BDNF antibody 1 conjugated with biotin (Sulfo-
NHS-LC-biotinylation kit EZ-Link, Pierce) in coating buffer
(25mMTris, 150mMNaCl, 0.1%BSA, 0.05%Tween 20, pH 7.2).
Following an overnight incubation, the plateswerewashedwith
0.1%Tween 20 in PBS (washing buffer) and then blocked for 2 h
with 4% BSA in PBS. To each well 150 l of incubation buffer
(0.1 M KH2PO4, 0.1 M Na2HPO4, pH 7.6) were added, followed
by 50 l of sample or BDNF standard. Mk lysates or recombi-
nant BDNF were incubated overnight at 4 °C with 10 g/ml
mouse anti-BDNF antibody 9 conjugatedwith horseradish per-
oxidase (activated peroxidase kit, EZ-Link Plus, Pierce). Mk
lysates were used at 1:3 in 0.1% Triton X-100 PBS. To test for a
potential release of BDNF from Mks into their incubation
medium, purified Mks were cultured on a 24-well plate and
incubated for 2 days at 37 °C with 5% CO2, in CellGro SCGM
medium containing 10 g/ml horseradish peroxidase-conju-
gated anti-BDNF antibody 9. The standard curve was estab-
lished in a parallel plate using various concentrations of recom-
binant BDNF incubated for 2 days in the same culture medium
without cells. The limit of detection is 1.25 pg of BDNFperwell.
After 2 days, the corresponding media (Mks and standard
curve) were collected and incubated for 3 h on a rotating plat-
form followed by a rinse with washing buffer. BM chemilumi-
nescence ELISA substrate POD (Roche Applied Science,
Mannheim,Germany) was added, and luminescencewasmeas-
ured with a microplate reader (FLUOstar Omega, BMG
labtech). Both standards and samples were determined in
triplicate.
Immunocytochemistry and Confocal Analysis—Mks were
cultured on 200 g/ml human fibrinogen-coated coverslips for
6 h (mouse and ratMks) or 36 h (humanMKs), fixed for 30min
in 4% paraformaldehyde in PBS, and permeabilized for 15 min
at room temperature with 0.5% Triton X-100 in PBS. Mks were
then blocked with blocking solution (10% donkey serum in PBS
containing 0.1%Triton X-100, PBT) for 1 h. Primary antibodies
were diluted in blocking solution at the following final concen-
trations/dilutions: 1:500 rabbit anti-PF4 and 10 g/ml mouse
anti-BDNF antibody 9. After 2 h of incubation at room temper-
ature, coverslips were washed three times with PBT and incu-
bated for 1 h with the secondary antibodies used at a 1:500
dilution in blocking solution or phalloidin/TRITC (at 1:50 dilu-
tion in blocking solution). After further washing with PBT,
labeled coverslips were mounted onto glass slides with DAPI-
containing mounting medium. Images were acquired at 63
magnification using a confocal microscope (LSM 780; Carl
Zeiss). Co-localization coefficient between BDNF and PF4 was
determined using the Zeiss co-localization coefficient software
(ZEN black 2011), which utilizes the Manders overlap coeffi-
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cient equation to quantify overlapping pixels. At least 15 cells
per sample were analyzed.
RNA Extraction, Retrotranscription, and Conventional and
Real Time Quantitative PCRs—Total RNA was extracted from
animal tissue (dissected hippocampi or lungs) usingTRIzol rea-
gent (Invitrogen) and cells (mouse, rat, and humanMKs) using
RNeasy kit (Qiagen, Valencia, CA) according to themanufactu-
rer’s instructions, including a DNase treatment. Human RNA
samples from hippocampus or lung were obtained from Clon-
tech. cDNA was prepared from 1,250 ng of total RNA using
random hexamers (Promega) and SuperScript III first-strand
synthesis system (Invitrogen). To analyze expression of mouse,
rat, and human BDNF exon-specific transcripts, cDNA was
amplifiedwith 35–40 cycles of PCRusing an annealing temper-
ature of 57–60 °C for all primer combinations (primers listed in
Table 1). Real time quantitative PCR was performed on the
StepOne system (Applied Biosystems, Invitrogen) using Taq-
Man probes and primers for mouse, rat, and human BDNF
exon-specific transcripts or BDNF coding sequence along with
the housekeeping genes GAPDH and rRNA18S (Applied Bio-
system, Invitrogen, primers listed in Table 2). To compare the
expression levels of theBDNFmRNAcoding sequence between
species, SYBR master mix (Applied Biosystems, Invitrogen)
was used together with the corresponding primers (Table 2).
Relative BDNF gene expression levels were calculated using the
2Ctmethod and the housekeeping genes for normalization.
The expression of proprotein convertases in rat Mks was ana-
lyzed using primers as described previously (17).
TABLE 1
Primers used in conventional PCR experiments
m is mouse; r is rat; and h is human.
Name of
oligonucleotide Sequence (5–3) Product size
mr BdnfI sense GTGTGACCTGAGCAGTGGGCAAAGGA 803 bp
mr BdnfII sense GGAAGTGGAAGAAACCGTCTAGAGCA 469 bp (IIa)
682,bp (IIb)
765,bp (IIc)
m BdnfIII sense GCTTTCTATCATCCCTCCCCGAGAGT 425 bp
r BdnfIII sense CCTTTCTATTTTCCCTCCCCGAGAGT 427 bp
mr BdnfIV sense CTCTGCCTAGATCAAATGGAGCTTC 553 bp
mr BdnfV sense CTCTGTGTAGTTTCATTGTGTGTTC 364 bp
m BdnfVI sense GCTGGCTGTCGCACGGTTCCCATT 542 bp
r BdnfVI sense GCTGGCTGTCGCACGGTCCCCATT 543 bp
mr Bdnf VII sense CCTGAAAGGGTCTGCGGAACTCCA 420 bp
mr Bdnf VIII sense GTGTGTGTCTCTGCGCCTCAGTGGA 362 bp
m Bdnf IXA sense CCCAAAGCTGCTAAAGCGGGAGGAAG
r Bdnf IXA sense CCAGAGCTGCTAAAGTGGGAGGAAG 525 bp
mr Bdnf antisense GAAGTGTACAAGTCCGCGTCCTTA
h BDNF sense GATGCCAGTTGCTTTGTCTTCTGTAG 471 bp
h BDNFII sense GGGCGATAGGAGTCCATTCAGCACC 311 bp (IIa)
526 bp (IIb)
609 bp (IIc)
h BDNFIII sense AGTTTCGGGCGCTGGCTTAGAG 346 bp
h BDNFIV sense GCTGCAGAACAGAAGGAGTACA 411 bp
h BDNFV sense TCGCGTTCGCAAGCTCCGTAGTG 272 bp (Va)
282 bp (Vb)
565 bp (V-VIII-VIIIh)
682 bp (V-VIII)
h BDNFVh sense GGCTGGAACACCCCTCGAA 339 bp
h BDNFVI sense GGCTTTAATGAGACACCCACCGC 368 bp (VIa)
386 bp (VIb)
493 bp (VI-IXb)
h BDNFVII sense GAACTGAAAGGGTCTGCGACACTCT 328 bp (VIIa)
428 bp(VIIb)
h BDNFIX sense TTTCTCGTGACAGCATGAGCAG 352 bp (IXabd)
536 bp (IXabcd)
h BDNF antisense GTCCTCATCCAACAGCTCTTCTATC
hmr HPRT sense GATGATGAACCAGGTTATGAC 469 bp
hmr HPRT antisense GTCCTTTTCACCAGCAAGCTTG
TABLE 2
Primers with references used in real time quantitative PCR experi-
ments
m is mouse; r is rat; and h is human.
Name of oligonucleotide Reference or sequence (5–3)
Prod-
uct
size
m Bdnf (coding
sequence)
Mm04230607_s1 92 bp
m BdnfI Mm01334047_m1 105 bp
m BdnfIV Mm00432069_m1 145 bp
m BdnfVI Mm01334042_m1 108 bp
m BdnfIXa Mm04230616_s1 77 bp
m Gapdh Mm99999915_g1 109 bp
m rRNA18S Mm03928990_g1 61 bp
r Bdnf (coding sequence) Rn02531967_s1 142 bp
r BdnfI Rn01484924_m1 106 bp
r BdnfIV Rn01484927_m1 120 bp
r BdnfVI Rn01484928_m1 109 bp
r BdnfIXA Rn04230568_s1 95 bp
r Gapdh Rn01775763_g1 174 bp
r rRNA18S Rn03928990_g1 61 bp
h BDNF (coding
sequence)
Hs02718934_s1 74 bp
h BDNFI Hs00538277_m1 104 bp
h BDNFIV Hs00380947_m1 116 bp
h BDNFVIa Hs04188535_m1 119 bp
h BDNFVIb Hs00156058_m1 143 bp
h BDNFIXabcd Hs00542425_s1 81 bp
h GAPDH Hs02758991_g1 93 bp
h rRNA18S Hs03003631_g1 69 bp
mrh BDNF sense (coding
sequence)
GAGCTGAGCGTGTGTGACAG 256 bp
mrh BDNF antisense
(coding sequence)
CGCCAGCCAATTCTCTTTTTGC
mrh rRNA18S sense GTCTGTGATGCCCTTAGATG 176 bp
mrh rRNA18S antisense AGCTTATGACCCGCACTTAC
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Statistical Analysis—All values are expressed as mean S.E.
All statistical tests were paired t test, one-tailed.
Results
To determine whether BDNF can be detected in Mks, we
established primary cultures ofmouse, rat, and humanMks and
analyzed their content by Western blotting using a BDNF
monoclonal antibody specifically recognizing BDNF and not
NGF or NT4, under conditions where both are recognized by
their corresponding antibodies (data not shown). A strong sig-
nal corresponding to the expected size of the monomer of
mature BDNF was detected in both rat and human but not in
mouse Mks (Fig. 1A). Note that pro-BDNF is barely detectable
under these conditions, with only a faint band detected in
human Mks. As a control, we also analyzed the BDNF content
FIGURE 1.Differential BDNF protein levels in mouse, rat, and humanmegakaryocytes and platelets.Western blot lysates of cultured Mks (A) and blood
platelets (B) are shown. Eightymicrograms of protein per lane were loaded, and the blottingmembranewas incubatedwith themousemonoclonal antibody
3C11 developed by Icosagen (Tartu, Estonia). Recombinant BDNF and pro-BDNF were used as molecular mass markers and antibodies to -actin as loading
controls. Asterisks (top right panels) point to a band unrelated to BDNF likely corresponding to immunoglobulin light chains in the mouse sample. Note the
absenceof BDNF inmouseMksandplatelets.C,antibodies toBDNF9 (green) (15) andPF4 (red) reveal expressionofbothantigens inmature rat andhumanMks.
Note that unlike PF4, BDNF is not detectable inmouseMks. The co-localization of BDNFwith PF4 in rat and humanMkswas quantified using the pixel intensity
specifically generated by each channel. In humans, 83% and in rats 86% BDNF-positive granules were also PF4-positive. Blue, DAPI staining. D, immunofluo-
rescence staining of F-actin (red) and BDNF (green) in proplatelet-forming cultured human Mks. Arrows indicate BDNF accumulation in proplatelet buds.
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of platelets purified from the corresponding species and con-
firmed the presence of considerable amounts of BDNF in
human platelets, with substantial levels also detected in rat but
not in mouse platelets (Fig. 1B). This result with platelets is in
agreement with previous conclusions using immunoassay
determinations with the serum prepared from these three spe-
cies (18). We then explored whether BDNF would be localized
in -granules, the storage compartment of a number of growth
factors in the Mk lineage. A BDNF-specific signal was found to
extensively co-localize with platelet factor 4 (PF4), also desig-
nated CXCl4, one of the most abundant -granule proteins
(Fig. 1C). A distinct BDNF signal could also be seen in the tips of
the proplatelet-forming humanMks (Fig. 1D, arrows), consist-
entwith the notion that BDNF is transferred fromMks to plate-
lets. As a control for the specificity of the BDNF signal in these
immunostaining experiments, we used mouse Mks. When
incubated with the corresponding antibodies under the same
experimental conditions as rat and human Mks, PF4, but not
BDNF, was detected (Fig. 1C). The lack of any detectable BDNF
in mouse platelets is not a feature specific to CD1mouse strain
that we used in most of our experiments, as the C57BL/6 strain
led to identically negative results, both inMks and platelets.We
note that in a recent highly sensitive andquantitative proteomic
analysis of C57BL/6 platelet extracts, no BDNF could be
detected (19). Quantification of the BDNF levels in rat Mks by
ELISA indicated that their lysates contain 1.40  0.13 ng/mg
protein (mean S.E., n 6). We also attempted to determine
whether proplatelet-forming Mks release BDNF into the
medium by incubating the cells with HRP-conjugated BDNF
monoclonal antibodies (see “Experimental Procedures”). After
2 days of incubation with the BDNF capture antibody, we failed
to detect any release of BDNF into the Mk-conditioned
medium, suggesting that the bulk of BDNF is transferred into
platelets and not released into the medium. This result is con-
sistent with the previous work indicating that both in rats and
humans the levels of BDNF are far higher in serum than in
plasma, suggesting that the bulk of BDNF in serum results from
platelet degranulation (18). To determine whether the BDNF
biosynthetic machinery is expressed in Mks, we isolated RNA
frommature platelet-formingmouse, rat, and humanMks. Sig-
nificant levels ofBDNFmRNAswere detected in both rat and in
human cells (Fig. 2A). In four separate experiments, the total
mRNA levels in both species were found to be about 200-fold
higher in rat and human, compared with mouse Mks. All
known BDNF transcripts present in RNA extracted from Mks
of the three species were analyzed and compared with RNA
extracted from the hippocampus and the lung as neuronal and
non-neuronal reference tissues of the corresponding species
(Fig. 2A). The results of these experiments revealed a neuronal
pattern of mRNA expression in both rat and human Mks, with
a prominent inclusion of exon I and IV transcripts. Notably,
exon I-containing transcripts have recently been shown to
markedly increase BdnfmRNA translatability (20). By contrast,
these typical neuronal transcripts were undetectable in the
mouse (Fig. 2A). The levels of all main transcripts were also
assessed in the three species by real time PCR (Fig. 2B).
In neurons, increased levels of cytoplasmic calciumhave long
been known to activate Bdnf transcription by activating pro-
moters I and IV in particular (21). AsMks are devoid of voltage-
activated calciumchannels, the addition of thapsigargin to non-
electrically excitable cells such asMks offered an opportunity to
test whether the corresponding Bdnf promoters are also
responsive to calcium levels in Mks. Thapsigargin is a selective
inhibitor of the sarco/endoplasmic reticulum Ca2-ATPase,
secondarily leading to the opening of stored-operated calcium
channels at the cell surface and increased levels of cytoplasmic
calcium (22). We found that at nanomolar concentrations (Fig.
3A), thapsigargin massively activates transcription in a time-
dependent manner (Fig. 3B). This increase was primarily
accounted for by contributions from exons I, IV, and IXa and to
a lesser extent exon VI (Fig. 3C). We then tested whether com-
plexing extracellular calcium would decrease the thapsigargin-
induced transcriptional activation of Bdnf and found that 2.5
mM EGTA completely blocked the inductive effects of thapsi-
gargin as assessed both by primers corresponding to the protein
coding sequence or by exon-specific primers (Fig. 3C). To fur-
ther test the notion that intracellular calcium levels regulate
Bdnf transcription, we tested the effects of the calcium iono-
phore ionomycin.When added tomatureMk cultures for 4 h, it
increased the levels of BdnfmRNA by 10.50 1.85-fold (n 3,
mean S.E.). As still very little is known about the biosynthesis
of endogenous BDNF in any cell type, we were then curious to
see how the Mk translation and processing machinery would
cope with the massive increase in BdnfmRNA levels caused by
thapsigargin.We found that at 10 nM, thapsigargin led not only
to amarked increase of processed (ormature) BDNF but also to
readily detectable levels of pro-BDNF, suggesting that the thap-
sigargin-induced increased transcription may temporarily sat-
urate the pro-BDNF processing capacity of Mks (Fig. 4, A–C).
The 3C11 BDNF monoclonal antibody recognizes not only
mature but also (as expected) unprocessed and partially pro-
cessed forms of BDNF as indicated in Fig. 4, A and B. In previ-
ous experiments using heterologous expression systems, we
noted that the replacement of an arginine residue in position
1 by lysine at the furin cleavage site of pro-BDNF led to the
accumulation of an N-glycosylated intermediate product cor-
responding to the size indicated by the arrows in Fig. 4,A andB.
Amino-terminal sequencing of this product indicated that the
use of an alternative cleavage site generated a product with a
15-residue addition to the amino terminus of mature BDNF
(23). This productwas shown to beN-glycosylated (21). The use
of the pro-BDNFmonoclonal antibody H1001G independently
confirmed the identity of pro-BDNFand also allowed the detec-
tion of the BDNF cleaved pro-peptide (Fig. 4C).We note that in
the absence of thapsigargin stimulation, the steady state levels
of pro-BDNF are even lower than in neurons where we esti-
mated them to represent about 1 molecule for 10 molecules of
mature BDNF (8, 15).We also tested the expression of themost
likely protease candidate thought to be involved in the genera-
tion of mature BDNF, namely furin and the proprotein conver-
tase 7, the latter having been recently shown to be necessary for
the processing of BDNF in neurons (24). The results of conven-
tional (Fig. 5A) and real time quantitative PCR (Fig. 5B) exper-
iments indicated that both enzymes are present in rat Mks, at
levels comparable with those found in the rat hippocampus
(Fig. 5). In line with this, the processing of pro-BDNF was
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largely prevented by the addition of the convertase inhibitor
decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone (data not
shown).
Discussion
The results obtained with primary cultures of Mks suggest
that these cells represent the main source of BDNF in platelets
as well as in serum. First, Mks contain readily detectable levels
of BDNF protein. Second, BDNF is stored in-granules inMks,
long known to also represent the storage compartment of var-
ious growth factors and cytokines in platelets (25). Third,
BDNF can be visualized in proplatelets (Fig. 1D) suggesting that
platelets contain BDNF by the time they begin to separate from
Mks. Fourth, the BDNF gene is expressed at relatively high lev-
els in rat and human Mks, although by contrast, the levels are
much lower in mice. Notably, the mouse transcripts do not
include exon I, which allows efficient translation of BDNF
mRNA (20). This negative result with mouse Mks is significant
as it correlates with the lack of detectable levels of BDNF in
mouse serum, unlike the case with rat and human sera (18).
Taken together, it would seem that circulating platelets, once
filled up with BDNF packaged in -granules inherited from
Mks, represent the only significant source of BDNF in serum.
Other sources such as endothelial or immune cells that do
express the BDNF gene at low levels (26, 27) do not seem to
make significant contributions to circulating levels of BDNF as
the levels are undetectable in mouse serum (18). Also, the very
low levels of BDNF found in human and rat plasma may in fact
be accounted for by microparticles or exosomes released from
platelets (28). It is intriguing to note that human platelets and
sera contain BDNF levels that are about 10 times higher than in
the rat. The reasons for this difference are unclear at this point,
as is the function of BDNF in platelets. The lack of BDNF in
mouse platelets suggests that whatever the biological role of
platelet-derived BDNF may be, it could be redundant in the
mouse with the function of other platelet-derived growth fac-
tors. A signaling system based on the circulation of small and
FIGURE 2. Transcriptional analysis of BDNF in mouse, rat, and human megakaryocytes. Conventional (A) and real time quantitative (B) PCR using exon-
specific primers with RNA extracted frommature cultured Mks, adult hippocampus (Hippo), and lung are shown. Note that in the mouse, the neuron-specific
transcripts, including exon I and IV, are not detected and that by contrast the transcript pattern resembles the non-neuronal pattern observed in lung tissue.
The converse is the case with RNA extracted from rat and human Mks with transcript patterns, including exon I and IV, that are characteristic of a neuronal
pattern as illustrated with the hippocampus. Unless indicated as non-significant (n.s.), all values are mean values  S.E. in triplicates and based on three
independent experiments, at p 0.001 (paired t test).
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ubiquitous cellular fragments, including exosomes loaded up
with a powerful neurotrophic factor, has the potential to be
functionally relevant in the context of humanbrain function.As
blood flow is tightly regulated by neuronal activity (29), it is
conceivable that in humans exosomes loaded with BDNF (30)
may be delivered to the brain in activity-dependent fashion,
possibly explaining the beneficial effects of physical exercise.
Although this is a matter of speculation at this point, the possi-
bility of a functional role for BDNF in platelets can now be
tested by engineering the mouse genome so as to replicate the
situation in humans.Alternatively, it is also conceivable that the
functional significance of BDNF in humanplateletsmay remain
as mysterious as that of NGF and EGF in the adult male mouse
submandibular gland (31).
Itmay seem surprising that the cellular source of BDNF in rat
and human serum has not been previously uncovered, espe-
cially in view of the very extensive use of BDNF as a biomarker
in human blood (32). An analysis of the corresponding litera-
ture reveals that negative results were obtained early on in
experiments specifically addressing the question of BDNF
expression in human Mks (16). These experiments were per-
formed with the megakaryocyte lines DAMI and Meg-01 and
led to the conclusion that theBDNF gene is not expressed in the
cells (16). Althoughwe confirmed these results, it appears plau-
sible that these tumor lines fail to faithfully replicate late aspects
of Mkmaturation, as is not rarely the case with readily expand-
able tumor cells. Following this negative result, the presence of
BDNF in platelets has been speculated to results from a hypo-
thetical uptake from sources such as the brain. However, this
notion has not been substantiated by plausible mechanisms,
unlike in the case of serotonin, a neurotransmitter long known
to accumulate in the dense granules of platelets following its
uptake by specific transporters located in the membrane of
platelets.
The identification of Mks as the source of BDNF in platelets
invites a revision of the widely held view that in humans the
serum levels of BDNF reflect its levels in the brain. In addition
to our findings, it has long been established that radiolabeled
BDNF does not reach the brain when injected into the periph-
eral circulation (33). It appears then that the variations in the
levels of BDNF reported in various conditions, including the
increase after physical exercise (14) or decrease during the
course of depressive episodes (13), are in need of alternative
plausible explanations, and it is conceivable that these varia-
tions may reflect different degrees of platelet activation (34). In
addition, there is emerging evidence that the hematopoietic
niche where Mks develop (35) is innervated by the peripheral
nervous system and that hematopoietic cells may respond to
nerve-derived signals (36).However, whether or not these stim-
uli change the expression levels of BDNF in Mks remains
unclear at this point.
With regard to the biosynthesis of endogenous BDNF, our
results suggest that Mks could represent an alternative cellular
model to neurons, which have been so difficult to study in the
face of the very low levels of expression of BDNF levels in these
cells. By comparison with BDNF levels in the brain (11), the
levels of BDNF in human platelets are significantly higher,
100–1,000-fold on a per mg of protein basis when brain
extracts and purified platelets are compared (12). In particular,
Mks offer a new opportunity to examine the biosynthesis of
endogenous BDNF and the possible role of pro-BDNF. Tran-
scription activation by thapsigargin leads to clearly detectable
levels of pro-BDNF without the need for prior enrichment by
immunoprecipitation. In view of the current interest related to
theVal3Met substitution in pro-BDNF (3), humanMks of the
corresponding genotype may represent an interesting cellular
model to understand the biochemical consequences of this
amino acid replacement.
FIGURE 3.Up-regulation of BdnfmRNA by thapsigargin. Effect of extracel-
lular calcium. Dose response (A) and time course (B) of BdnfmRNAexpression
by rat Mks after thapsigargin treatment. Purified mature rat Mks were cul-
tured in the presence or absence of thapsigargin or vehicle (DMSO) used at
the indicated concentrations (A) and for different lengths of times (B). Total
mRNA was extracted and reverse-transcribed, and the resulting cDNA was
amplified by real time quantitative PCR using specific primers for the coding
sequence of Bdnf. C, extracellular calcium dependence of thapsigargin-in-
duced BdnfmRNA increase. RatMkswere preincubatedwith 2.5mM EGTA for
1.5 h at 37 °C followed by 10 nM thapsigargin for 4 h. mRNA expression was
analyzed by real time quantitative PCR using specific primers for the coding
sequence of Bdnf (CDS) or exon-specific primers. All values aremean values
S.E. in triplicates and based on three independent experiments. Unless indi-
cated, all the statistical values are compared with the control. *, p 0.05; ***,
p 0.001 (paired t test).
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FIGURE 4. Effect of thapsigargin on pro-BDNF,mature BDNF, and pro-peptide in ratMks.Dose response (A) and time course (B) of pro-BDNF andmature
BDNF proteins by rat Mks after thapsigargin treatment are shown. Mature Mks were cultured for 16 h at the indicated doses of thapsigargin (A) or 10 nM
thapsigargin for the indicated times (B). Forty micrograms of protein per lane were loaded, and the blotting membrane was incubated with the mouse
monoclonal antibody 3C11 developed by Icosagen. Arrows indicate intermediate proteolytic products of pro-BDNF (C). Time course of pro-BDNF and pro-
peptide proteins generated by ratMks incubatedwith 10 nM thapsigargin for the indicated timeperiods. Eightymicrograms protein per lanewere loaded, and
the blotting membrane was incubated with the mouse monoclonal antibody H1001G developed by GeneCopeia, Inc. The blots shown are representative of
three independent experiments with similar results. Graphs show mean  S.E. of the densitometric values quantified from the blots of the three separate
experiments. ***, p 0.001 (paired t test compared the corresponding controls). Recombinant BDNF (150–300 pg), cleavage-resistant recombinant pro-BDNF
(0.5–1 ng), and recombinant pro-peptide (1–10 ng) were used as molecular mass markers and antibodies to -actin as loading controls.
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In conclusion, our results contribute to clarify the cellular
origin of BDNF in human blood; and they describe a tractable
cellular system to study the biosynthesis of endogenous BDNF.
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